Infectious safety profile for the use of biological therapy in asthma with mepolizumab and omalizumab

Perfil de seguridad infecciosa para el uso de terapia biológica en asma con mepolizumab y omalizumab

Published 2018-05-10

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 29 No. 2 (2017)
Section
Topics review
How to Cite
Infectious safety profile for the use of biological therapy in asthma with mepolizumab and omalizumab.
rev. colomb. neumol. [Internet]. 2018 May 10 [cited 2024 Nov. 24];29(2):39-45. Disponible en: https://doi.org/10.30789/rcneumologia.v29.n2.2017.266
DOI

https://doi.org/10.30789/rcneumologia.v29.n2.2017.266
Dimensions
PlumX
license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Carlos Eduardo Pérez Díaz
Médico Infectólogo Clínica Marly. Presidente, Servicios y Asesorías Infectología (SAI) (CC 79.471.917 de Bogotá).
    Francisco Javier Africano Díaz
    Médico General, Servicios y Asesorías Infectología (SAI).
      Maryi Viviana Estrada Bonilla
      3 Médico General, Servicios y Asesorías Infectología (SAI) (CC 1.014.209.334)
        Martha Díaz Gómez
        Médica Interna, Universidad de La Sabana (CC 1.072.700.268).
          Show authors biography
          The advent of biological therapy for the treatment of multiple diseases, has been related to the reactivation or susceptibility to certain infectious entities during its use. The understanding of asthma physiopathology has led to the recognition of diverse and distinctive mechanisms of the disease, allowing the development of targeted biological therapies directed to the underlying systemic disease process and resulting in a greater benefit for patients. Until present, these therapies have demonstrated a pronounced impact on symptoms improvement and on patient life quality; however, it is now being plausible the appearance of infectious diseases, such as viral respiratory infections and susceptibility to parasitism, among the most important illnesses related to mechanism of action of biological therapies used in asthma. In this narrative review we described the most recent findings found about infectious safety profile for the use of biological therapy in asthma with Mepolizumab and Omalizumab, being those two the most used biological therapies used in treatment of severe refractory asthma; with the purpose of announce the infectious risks of this molecules and generate some recommendations for prevention and management of this risks in our Latinamerican context.

          Article visits 1021 | PDF visits 874

          Downloads

          Download data is not yet available.
          1. Walsh G. An update on biologic-based therapy in asthma. Immunotherapy. 2013;5(11):1255-64. DOI: 10.2217/imt.13.118.
          2. Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Current Opin Pulm Med. 2014;20(1):8794. DOI: 10.1097/MCP.0000000000000007.
          3. Bice JB, Leechawengwongs E, Montanaro A. Biologic targeted therapy in allergic asthma. Ann Allergy Asthma Immunol. 2014;11(2):108-15. DOI: 10.1016/j.anai.2013.12.013.
          4. Mitchell PD, El-Gammal AI, O’Byrne PM. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clin Pharmacol Ther. 2016;99(1):38-48. DOI: 10.1002/cpt.284.
          5. Keating G. Mepolizumab: First global approval. Drugs. 2015;75(18):2163-9. DOI: 10.1007/s40265-015-0513-8.
          6. Farmacovigilancia.invima.gov.co. (2018). Sistema de Trámites en Linea - Consultas Públicas [Internet]. Disponible en: http://farmacovigilancia.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp [con acceso en febrero 5, 2018].
          7. Product information XOLAIR(R). Subcutaneous injection powder, omalizumab subcutaneous injection powder. Genentech, Inc. 2014.
          8. Incorvaia C, Mauro M, Russello M, Formigoni C, RiarioSforza GG, Ridolo E. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther. 2014;8:197-207. DOI: 10.2147/DDDT.S49409.
          9. Kelly BT, Grayson MH. Immunoglobulin E, what is it good for? Ann Allergy Asthma Immunol. 2016;116(3):183-7. DOI: 10.1016/j.anai.2015.10.026.
          10. Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197-207. DOI: 10.1111/j.13652222.2007.02650.x.
          11. Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy. 2008;63(4):409-17. DOI: 10.1111/j.1398-9995.2007.01601.x.
          12. Skiepko R, Zietkowski Z, Skiepko U, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Echinococcus multilocularis infection in a patient treated with omalizumab. J Investig Allergol Clin Immunol. 2013;23(3):197-211.
          13. Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-9. DOI: 10.1185/03007995.2010.539502.
          14. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):182-8. DOI: https://doi.org/10.1016/S1081-1206(10)62175-8.
          15. Somerville L, Bardelas J, Viegas A, D’Andrea P, Blogg M, Peachey G. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2014;30(1):59-66. DOI: 10.1185/03007995.2013.844115.
          16. McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs. 2014;74(14):1693-9. DOI: 10.1007/s40265-014-0290-9.
          17. Gonçalves R, Valente C, Ferreira E, Serra JE, da Cunha JS. Cytomegalic hepatitis in a patient receiving omalizumab. ID-Cases. 2016;5:83-4. DOI: 10.1016/j.idcr.2016.08.001.
          18. Shrimanker R, Pavord I. Interleukin-5 inhibitors for severe asthma: rationale and future outlook. BioDrugs. 2017;31(2):93-103. DOI: 10.1007/s40259-017-0215-8.
          19. Trivedi A, Pavord I, Castro M. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. Lancet Respir Med. 2016;4(7):585-92. DOI: 10.1016/S2213-2600(16)30018-2.
          20. ADIS R&D Profile. Mepolizumab. 240563, Anti-IL-5 Monoclonal antibody-GlaxoSmithKline, anti-interleukin-5 monoclonal antibody-GlaxoSmithKline, SB 240563. Drugs in R & D. 2008;9(2);125-30. DOI: https://doi.org/10.2165/00126839-200809020-00006.
          21. Molfino NA, Gossage D, Kolbeck J, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy. 2012;42(5):71237. DOI: 10.1111/j.1365-2222.2011.03854.x.
          22. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9. DOI: 10.1016/S01406736(12)60988-X.
          23. Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2013;8(3):e59872. DOI: 10.1371/journal.pone.0059872.
          24. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058-70. e1. DOI: 10.1016/j.clinthera.2016.07.010.
          25. Powell C, Milan SJ, Dwan K, Bax L, Walters N. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;(7):CD010834. DOI: 10.1002/14651858.CD010834.pub2.
          26. Product information NUCALA(R). Subcutaneous injection, mepolizumab subcutaneous injection. GlaxoSmithKline. 2015.

          Information

          Journal history

          Keywords

          QR code

          Funding

          Support + Info: Here

           

           

          Directories and indexes

          Google Scholar profile

          Most read in the last 30 days

          Current Issue

          Sistema OJS 3.4.0.7 - Metabiblioteca |